Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II StudyAndrew B. Lassman, Patrick Roth, Juan Manuel Sepúlveda-Sánchez et al.|Zurich Open Repository and Archive (University of Zurich)|2022Cited by 76
Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor Haizhong Feng, Shi‐Yuan Cheng, Yaxian Li et al.|Neuro-Oncology|2014Cited by 35
1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)Anthony J. Olszanski, Xīn Gào, Jason J. Luke et al.|Annals of Oncology|2023Cited by 14
OS10.6 Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II studyAndrew B. Lassman, Patrick Roth, Juan Manuel Sepúlveda-Sánchez et al.|Neuro-Oncology|2019Cited by 11
Supplementary Figure 6 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with GlioblastomaErik Ladomersky, Derek A. Wainwright, Lijie Zhai et al.|Unknown|2023Cited by 0